Arcutis Biotherapeutics, Inc. (ARQT) Tops Q4 EPS by 19c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q4 EPS of ($0.09), $0.19 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $71.3 million versus the consensus estimate of $54.72 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• PG&E Corp, Edison spike on chatter
• Uniserve CEO Gautam Lohia to Speak at CanITCon 2026; Supports UBC Sauder Powerhouse Project
• LP Building Solutions to halt OSB output at Texas plant in October